However, the overall impact of CDK4/6 i-based therapy on peripheral blood counts in PALOMA, MONARCH, and MONALEESA trials has not been accurately discussed, and only a single case study describes a patient who developed neutropenia, thrombocytopenia, and anaemia following a palbociclib regimen [36]. This evidence concerns the gene CDK4 and anemia.